CXCL12 and neoplasm: To confirm that CXCR4:CXCL12 axis contributes to the seeding of the bone chip at the metastatic site, we repeated the tumor xenograft at the primary site and the human bone at the metastatic site experiment with the addition of AMD3100, a CXCR4 inhibitor.